PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Global leaders in the fight against cancer gathered in Washington, DC on October 18, 2024, for the NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship

2024-10-28
(Press-News.org) Washington, DC –  The 2024 National Foundation for Cancer Research (NFCR) Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted with the AIM-HI Accelerator Fund, convened the world’s top experts across cancer research, biotech entrepreneurship, pharmaceuticals, investment, and patient advocacy. This prestigious event, held at the National Press Club, served as a unique forum for advancing groundbreaking science, fostering innovative collaborations, identifying critical unmet needs for patients, and driving forward breakthrough solutions. This event highlighted cutting-edge cancer research advancements, the emerging area of early detection and early intervention research, utilizing artificial intelligence (AI) in improving cancer diagnostics, drug development, and personalized treatment strategies—revolutionizing the future of cancer care.

An Event that Consistently Addresses the Critical Unmet Needs for Cancer Patients The NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship is organized every year to foster groundbreaking collaborations across the cancer research ecosystem. Each year, this event brings together researchers, clinicians, community physicians, biotech/biopharma entrepreneurs, biotech investors, cancer survivors, and advocates to create actionable strategies to directly impact cancer care. Critical discussions initiated at this summit become the launch-pad for future advancements in research and drug diagnosis and treatment—ensuring that the fight against cancer moves forward with a decisive purpose and a worldwide movement from all aspects of the cancer-addressing ecosystem.

A Unique and Essential Gathering for Cancer Research and Collaboration The collaborative efforts formed here are advancing research and creating a future where curing cancer is possible. Leaders from across the globe come together to share insights, build partnerships, challenge the barriers and status quo, and work collectively toward a common goal: to save lives. The 2024 NFCR Global Summit showcased powerful exchanges of knowledge, insights, and visions that will create positive ripple effects in cancer research and patient care for years to come.

Keynotes on Cancer Breakthroughs The event began with a keynote address from Drew Pardoll, M.D., Ph.D. (Johns Hopkins University Medical School), who discussed the transformative impact of checkpoint inhibitors on cancer immunotherapies. Dr. Pardoll addressed the urgent need for biomarkers to predict patient responses, improved clinical trials, and emphasized the need for better combination therapies to make immunotherapy more effective for a broader range of cancer patients.

Pulitzer Prize-winning author Siddhartha Mukherjee, M.D., delivered the evening keynote, fully engaging the audience with his fascinating stories about how cancer care has evolved over a long period.  Weaving history and personal anecdotes, he captivated the audience and he shared his vision for the future of cancer treatment. Focusing on the evolving landscape of gene editing, cellular engineering, and the pivotal role AI-powered immunotherapies will play in shaping the next decade of cancer care. Dr. Mukherjee explained that, by leveraging AI and utilizing mature and low cost drug manufacturing capabilities in India, he expects to produce some treatments such as the CDK-4/6 inhibitor, palbociclib, at just 1/10th to 1/20th the cost of traditional drugs. This forward-looking approach to cancer treatment production has the potential to profoundly impact countless lives and improve access equity for underserved populations in the U.S. and worldwide.

Cutting-Edge Discussions: Panel on New Approaches to Cancer Treatments During this panel, innovative ideas and emerging areas in cancer treatment were discussed, with a strong emphasis on the critical need for personalized approaches. The session helped create a clear action plan for advancing research and developing new treatment strategies. Lisa Coussens, Ph.D. (Oregon Health & Science University) moderated the panel featuring:

Aditya Bardia, M.D. (University of California, Los Angeles) spoke about Antibody-Drug Conjugates (ADCs) for HER2-positive breast cancer, a game-changing approach that could significantly reduce chemotherapy toxicity. Jonathan Chernoff, M.D., Ph.D. (Fox Chase Cancer Center) discussed molecular glues and their role in targeting previously “undruggable” proteins, focusing on RAS-driven cancers. Scott Lippman, M.D. (University of California, San Diego) spoke on cancer interception strategies, including the use of cell-free DNA (cfDNA) for early detection and prevention, now being amplified by machine learning algorithms to improve targeted precision medicine therapies. Paul Mischel, M.D. (Stanford University) presented his groundbreaking work with extra-chromosomal DNA (ecDNA), a key driver of treatment resistance in glioblastoma and other aggressive cancers, and how AI-powered data analysis is expediting ecDNA research. Shaping the Future of Cancer Care: Panel on Early Detection and Cancer Prevention Carlos Doti, M.D. of AstraZeneca, moderated this panel of key leaders to explore current unmet needs, emerging technologies, clinical and policy challenges of implementing cancer screening, and potential strategies that could significantly improve patient outcomes:

Ajay Goel, Ph.D. (City of Hope) presented the promise of liquid biopsies for detecting cancer at its earliest stages, allowing for earlier interventions and better patient outcomes. AI-powered analysis is accelerating the accuracy of liquid biopsy results. Samir Hanash, M.D., Ph.D. (MD Anderson Cancer Center) discussed multi-omic approaches for discovering biomarkers, urging the integration of genomic, proteomic, and metabolomic data for earlier and more accurate detection—now more feasible thanks to AI-enhanced data mining techniques. Dr. Hanash confidently stated, “I guarantee that by the end of the decade, there will be vaccines for breast cancer.” This visionary foresight promises to change the lives of countless individuals at risk for the disease. Steven Lipkin, M.D., Ph.D. (Weill Cornell Medicine) and Sapna Syngal, M.D., MPH (Dana-Farber Cancer Institute) provided insight into genetic predispositions to cancer and the development of molecular diagnostics, which are increasingly benefiting from AI-driven advancements to prevent cancer in high-risk populations. Bridging the Gap Between Bench and Bedside Sessions organized by the AIM-HI Accelerator Fund (AIM-HI) were dedicated to advancing entrepreneurs and their biotech startups in development of promising therapies in the pre-clinical stage. Moderated by Matt Tremblay, Ph.D. (Board Chair of AIM-HI and CEO of Blackbird Laboratories), this session highlighted two critical elements in the fight against cancer.  The first panel showcased advancements from emerging and innovative early-stage oncology companies, while the second panel centered on the investor perspective, offering crucial insights into the needs for investment and growth potential of cutting-edge oncology startups. By bringing together top investors and emerging oncology entrepreneurs, AIM-HI cultivated a collaborative environment aimed at driving progress in cancer research.

Innovative Oncology Company Showcase The Innovative Oncology Company Showcase, spotlighted the rising stars of biotech innovation. Featuring updates from pioneering companies at the intersection of innovation and cancer research:

Adventris Pharmaceuticals (CEO: Jenny Lesser Herbach, MBA, and Co-Founder & CMO Mark Yarchoan, M.D.) presented its work on small molecule therapies targeting cancer cell signaling in triple-negative breast cancer. Adventris aims to bring its first drug candidate into clinical trials by 2025. Georgiamune (CEO: Samir Khleif, M.D.) highlighted combination immunotherapies that enhance the body’s natural defenses against cancer. CLASP Therapeutics (CSO: Vipin Suri, Ph.D.) discussed precision medicines targeting p53 mutations in solid tumors. Dr. Suri highlighted CLASP’s upcoming IND submission for a new treatment targeting p53 mutations. Degron Therapeutics (CEO: Lily Zou, Ph.D.) showcased its protein degradation platform, which is designed to treat drug-resistant cancers. Biolojic Design (CMO: Ronald Herbst, Ph.D.) presented bispecific antibody therapies for the enhanced immune response against cancer. Panel on Investor Perspectives on Innovative Oncology Companies An engaging investor panel, featured insights from leading biotech investors, including Dave Greenwald, Ph.D. (Deerfield), Beverly Lu, Ph.D. (Yosemite), Marie-Claire Peakman, Ph.D. (Pfizer Ventures), and Fei Shen, Ph.D. (BI Venture Fund), who discussed the strategic importance of investing in high-risk, high-reward oncology startups. The panel stressed that investors not only provide financial support but also help startups navigate regulatory hurdles, prioritize resources, and connect with broader networks. Despite the risks, the panel emphasized that continued investment in oncology is essential for developing groundbreaking therapies that can significantly improve patient outcomes.

2024 AIM-HI Beacon Award for Women Leaders in Oncology

The Beacon Award recognizes outstanding women leaders in all sectors of the health and life sciences industry, the 2024 AIM-HI Beacon Award was presented to Margaret Foti, Ph.D., M.D. (hc), CEO of the American Association for Cancer Research (AACR), in recognition of her groundbreaking leadership in cancer research and dedication to advancing innovation. In her acceptance remarks, Dr. Foti underscored the critical importance of addressing disparities in cancer care and expanding access to cutting-edge therapies across the globe.

The 2024 Szent-Györgyi Prize for Progress in Cancer Research

The prestigious 2024 Szent-Györgyi Prize for Progress in Cancer Research was awarded to Dennis Slamon, M.D., Ph.D. (UCLA Health, Jonsson Comprehensive Cancer Center) for his groundbreaking work that defined HER2+ breast cancer, contributing to the development of Trastuzumab (Herceptin), the translational research efforts on CDK-4/6 inhibitor, palbociclib. Both drugs now approved by the FDA. Significantly improving the prognosis for high-risk breast cancer patients. Dr. Slamon’s contributions have transformed the lives of countless patients worldwide and set a new standard in precision oncology.

The Future of Cancer Research Panel

The evening culminated with a panel discussion emceed by award-winning journalist Kristen Berset-Harris, WUSA9 Great Day Washington, featuring Dennis Slamon, M.D., Ph.D., Margaret Foti, Ph.D., M.D. (hc), Siddhartha Mukherjee, M.D., Olufunmilayo Olopade, M.D., Mohit Manrao, MBA, and patient advocates, Shereen and Isabella Pavlides, NFCR Ambassadors. The panel focused on each person’s views on the needs and trends of future cancer research, covering topics such as the growing importance of early detection technologies, the challenges posed by drug resistance, and the need for greater collaboration between the public and private sectors to accelerate the development and delivery of innovative treatments.

Testimonials Following the Event


The 2024 NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship provided a lasting perspective for attendees, highlighting the power of collaboration and innovation in the fight against cancer. Participants were energized by the groundbreaking discussions, actionable insights, and the potential for new partnerships to accelerate progress in cancer research and treatment. Below are a few testimonials from key figures who shared their thoughts on the event’s impact and importance.

“I thought that the meeting was excellent. We had great people, it was informational, intimate and very enjoyable. I saw many friends and met many new people. The meeting also reflected new trends in cancer research and care and provided new avenues for support from NFCR and investments by AIM-HI. Thank you for including me in these activities and festivities during the Global Summit.”

Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School 

“It’s been a great experience and very inspiring event to learn more about cancer research and how different sectors in the healthcare industry can contribute to improving the lives of cancer patients. What is unique about NFCR’s summit is that it gathers experts and leaders from research, healthcare, pharmaceuticals, and investment together to discuss and think about what needs to be done to move cancer care forward and how different parties can contribute to the progress.  The focus on big-picture views and forward-thinking is really great! I will definitely join you again next year.”

Ling Huang, Ph.D., Henry Ford Health Pancreatic Cancer, Michigan State University School of Medicine

“I was really impressed with what you have built and how your organization is a force for driving innovation and research.”

Mohit Manrao, SVP, Head of US Oncology | President, AstraZeneca Foundation

Looking Ahead: Save the Date for 2025

The next NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship will take place on October 24, 2025 at the National Press Club in Washington, DC, once again gathering the leading voices in cancer research, biotechnology, and patient advocacy to continue the fight against cancer through collaboration. For sponsorship information, please contact Brian Wachtel, NFCR Executive Director and CDO at bwachtel@nfcr.org. Follow NFCR on social media for ticket information concerning this limited space event.

About the Szent-Györgyi Prize for Progress in Cancer Research
The Szent-Györgyi Prize for Progress in Cancer Research was established in 2006 by the National Foundation for Cancer Research in honor of its co-founder, Albert Szent-Györgyi, M.D., Ph.D., recipient of the 1937 Nobel Prize for Physiology and Medicine. The award recognizes outstanding scientists whose seminal discovery or pioneering body of work has contributed to cancer prevention, diagnosis, or treatment and has had a lasting impact on understanding cancer, holding the promise of improving or saving the lives of cancer patients.

About the AIM-HI Beacon Award for Women Leaders in Oncology
The AIM-HI Beacon Award for Women Leaders in Oncology was established in 2022 by the AIM-HI Accelerator Fund and sponsored by the National Foundation for Cancer Research (NFCR). The Beacon Award recognizes outstanding women leaders in all sectors of the health and life sciences industry who have significantly impacted cancer treatment, detection, and diagnosis for patients worldwide through the development and commercialization of novel technologies, advocacy, and/or implementation of public policy.

About the National Foundation for Cancer Research
The National Foundation for Cancer Research (NFCR) is a 501(c)(3) nonprofit organization co-founded in 1973 by Nobel Laureate Dr. Albert Szent-Györgyi and Attorney/Business Entrepreneur Franklin Salisbury, Sr. NFCR provides scientists in the lab with the critical seed funding they need to make game-changing discoveries in cancer detection, treatments, prevention, and ultimately, a cure for all cancers. NFCR has distinguished itself in the cancer research sector by emphasizing “high-risk, high-impact” long-term and transformative pioneering research fields often overlooked by other major funding sources. With the support of more than 5.3 million individual donors over the last 50+ years, NFCR has provided more than $415 million in funding to cancer research, prevention, and public education. NFCR-supported research has led to some of the most significant life-saving discoveries that benefit patients today. To learn more, visit NFCR.org.
 

About the AIM-HI Accelerator Fund
The AIM-HI Accelerator Fund (AIM-HI) is a 501(C)(3) non-profit organization created in 2019 by the National Foundation for Cancer Research to provide oncology startups with the resources they need to drive innovative discoveries forward, out of the lab, to the clinics, and eventually to the people battling cancer. Our mission is to bridge the gap between research breakthroughs and clinical trials, aiming to develop innovative cancer therapies and technologies that can save patients’ lives. For more information, visit AIM-HIaccelerator.org.

END



ELSE PRESS RELEASES FROM THIS DATE:

New research highlights economic and employment challenges for parents of medically complex babies

New research highlights economic and employment challenges for parents of medically complex babies
2024-10-28
Parents with babies born preterm or with low birth weight face significant economic and employment challenges, according to new research published in JAMA Pediatrics. The study, led by Erin Von Klein, MD, a neonatology fellow at Monroe Carell Jr. Children’s Hospital at Vanderbilt, reveals that 30% of parents with a very low birth weight baby (under 1,500 grams or 3.3 pounds) have had to make an employment decision based on their child’s health and the required ongoing care after discharge from the neonatal intensive care unit. "The lower the child's birth weight, the more likely a parent was to make one of these decisions," said Von Klein. "Of parents with ...

Prenatal cannabis exposure and executive function and aggressive behavior at age 5

2024-10-28
About The Study: Results from this contemporary U.S. cohort where prenatal cannabis exposure was common and indicated that exposed children exhibited some differences in aspects of executive function and behavior relevant to long-term academic success and adaptive functioning. These results may be considered in refining clinical recommendations regarding cannabis use during pregnancy. Corresponding Author: To contact the corresponding author, Sarah A. Keim, PhD, email sarah.keim@nationwidechildrens.org. To ...

BMI and postacute sequelae of SARS-CoV-2 infection in children and young adults

2024-10-28
About The Study: In this cohort study, elevated body mass index (BMI) was associated with a significantly increased post-acute sequelae of SARS-CoV-2 infection risk in a dose-dependent manner, highlighting the need for targeted care to prevent chronic conditions in at-risk children and young adults.  Corresponding Author: To contact the corresponding author, Yong Chen, PhD, email ychen123@pennmedicine.upenn.edu. To access the embargoed study: Visit our For The Media website at this link ...

Cannabis use during pregnancy can impact thinking and learning skills, increase aggression among children, study shows

2024-10-28
(COLUMBUS, Ohio) – As cannabis is legalized and is more accessible in various forms across the country, there is increasing concern among health care providers about potential impact on children. Researchers at Nationwide Children’s Hospital have new findings to add to the existing evidence that cannabis exposure before birth can negatively impact children. In a study published today in JAMA Pediatrics, researchers found prenatal cannabis exposure was associated in early childhood with poorer thinking skills and behaviors such as impulse control, paying attention, planning ability, and more aggressive behavior, all of ...

Children’s Hospital of Philadelphia researchers discover underlying mechanisms that make CRISPR an effective gene editing tool

2024-10-28
Philadelphia, October 28, 2024 – CRISPR/Cas9 is a gene editing tool that has revolutionized biomedical research and led to the first FDA-approved CRISPR-based gene therapy. However, until now, the precise mechanism of exactly how this tool works and avoids creating detrimental off-target effects was not well understood. Now, using state-of-the-art technology, researchers from Children’s Hospital of Philadelphia (CHOP) have identified several specific steps needed for CRISPR to become active and perform its gene editing function. These preclinical findings could lead to improved designs for CRISPR-based ...

Age-period-cohort analysis of cutaneous malignant melanoma incidence in the United States from 1987 to 2016

2024-10-28
Background and objectives The prevalence and fatality rates of cutaneous malignant melanoma (CMM) have been rising, particularly among the elderly. This study analyzes CMM incidence trends in the United States elderly population from 1987 to 2016 to inform prevention and management strategies. Methods Using incidence data from the Surveillance, Epidemiology, and End Results database spanning 1989 to 2008, we calculated the age-adjusted standardized population incidence rates for CMM in elderly individuals. The Joinpoint ...

NCCN Cancer Center study demonstrates usability of Health Equity Report Card (HERC) tool for driving fair access to care

2024-10-28
MINNEAPOLIS, MN [October 28, 2024] — Today, the National Comprehensive Cancer Network® (NCCN®) is presenting preliminary data from a study evaluating the usability of the Health Equity Report Card (HERC) tool during the American Public Health Association (APHA) Annual Meeting and Expo. The HERC was created by the Elevating Cancer Equity collaboration between NCCN, the American Cancer Society Cancer Action Network (ACS CAN), and the National Minority Quality Forum (NMQF) and updated by a subsequent working group. It features 19 practice evaluation and change recommendations designed to help providers and healthcare organizations identify and address disparity and bias in care ...

SwRI adds new chamber for spacecraft-related EMC, EMI testing

SwRI adds new chamber for spacecraft-related EMC, EMI testing
2024-10-28
SAN ANTONIO — October 28, 2024 —Southwest Research Institute (SwRI) has added a semi-anechoic shielded enclosure for electromagnetic compatibility and interference (EMC/EMI) testing for spacecraft. The test chamber is the next step in SwRI’s plans to create a turnkey spacecraft integration and test center within its 74,000-square-foot Space System Spacecraft and Payload Processing Facility. The 400-square-foot EMC/EMI Chamber is semi-anechoic, or free of echo, and shielded from electromagnetic interference. It supports performance of standard emissions and susceptibility testing with an upper frequency limit of 40 gigahertz ...

Molecular profiling using next-generation sequencing of sufficient endobronchial ultrasound-guided transbronchial needle aspiration and liquid biopsy samples in patients with advanced lung cancer

2024-10-28
Background and objectives Tumor molecular analysis using next-generation sequencing (NGS) is the standard of care for guiding lung cancer treatment. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive technique used to sample mediastinal lymph nodes for diagnosing and staging lung cancer. This study aimed to determine if EBUS-TBNA provided adequate tissue samples for NGS. Methods We evaluated EBUS-TBNA samples from adult advanced non-small cell lung cancer patients who had both ...

Case Western Reserve University awarded $2.6 million to study impact of high blood-pressure medications on chronic kidney disease patients

Case Western Reserve University awarded $2.6 million to study impact of high blood-pressure medications on chronic kidney disease patients
2024-10-28
CLEVELAND—The National Institutes of Health awarded a four-year, $2.6 million grant to researchers at Case Western Reserve University to study how high blood-pressure drugs affect patients with chronic kidney disease (CKD). More specifically, they want to study whether such medications increase the risk of kidney and cardiovascular disease in CKD patients. More than one in seven Americans suffer from CKD, according to the U.S. Centers for Disease Control and Prevention (CDC). CKD is a condition where ...

LAST 30 PRESS RELEASES:

Mathematical model illuminates how environment impacts life choices of salmon

Houston Methodist researchers shed light on increased rates of severe human infections caused by Streptococcus subspecies

Auburn University hosts 62nd Hands-On Workshop on Computational Biophysics, featuring the new VMD 2.0

The Salton Sea — an area rich with lithium — is a hot spot for child respiratory issues

University of Maryland-YouGov poll: Alsobrooks dominates Hogan, amendment to state constitution garners broad support

Exposure to particular sources of air pollution is harmful to children’s learning and memory, a USC study shows

Change of ownership in home health agencies may lead to increased Medicare spending and reduced staffing levels, according to UTHealth Houston research

More resources needed to protect birds in Germany

Mission to International Space Station launches research on brain organoids, heart muscle atrophy, and cold welding

nTIDE November 2024 Jobs Report: Disability employment remains near historic highs over past 18 months

Researchers aim to streamline cancer detection with new method for liquid biopsies

New Huntington’s treatment prevents protein aggregation

Bee gene specifies collective behavior

Jennifer Bickel, M.D., named MD Anderson Vice President and Chief Wellness Officer

Evolutionary paths vastly differ for birds, bats

Political pros no better than public in predicting which messages persuade

Investment in pediatric emergency care could save more than 2,100 young lives annually

The dynamic core of black holes

Improving energy production by boosting singlet fission process

Smoking cessation and incident cardiovascular disease

Cannabis use during early pregnancy following recreational cannabis legalization

Research shows Cleveland Clinic’s therapeutic virtual yoga program can be effective for chronic low back pain

Closing in on Parkinson’s Disease proteins in extracellular vesicles in the blood

Regional and global experts convene in Accra, Ghana to update cancer treatment guidelines for Sub-Saharan Africa

China University of Geosciences (Beijing) unveils clues to an enigmatic geological process

Fueling greener aviation with hydrogen

Education, occupation, and wealth affect the risk of cognitive impairment

Revealing causal links in complex systems

Alzheimer disease as a clinical-biological construct— an international working group recommendation

Press registration now open for the EULAR 2025 Congress in Barcelona

[Press-News.org] Global leaders in the fight against cancer gathered in Washington, DC on October 18, 2024, for the NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship